Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 5/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CDK3 | Q00526 | 3/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 3/20 | 0.53 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | WNT3A | P56704 | 3/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | RIOK2 | Q9BVS4 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383737 | 0.89 | CDK9 (0.64) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL12293756 | 0.87 | CDK9 (0.52) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2380679 | 0.87 | WNT3A (0.57) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2382635 | 0.86 | MAPK10 (0.61) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2381445 | 0.83 | CDK9 (0.52) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2383682 | 0.83 | CDK9 (0.63) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2383264 | 0.83 | GSK3B (0.53) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2381093 | 0.80 | WNT3A (0.57) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2383013 | 0.80 | CDK1 (0.69) | CDK9CDK1CDK2CDK3CDK5 | |
| SCHEMBL2381404 | 0.80 | CDK9 (0.52) | CDK9CDK1CDK2CDK3CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | claimed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | claimed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | claimed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CDK9 26/4885CDK1 1/4885CDK2 2/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | CDK9 26/4885CDK1 1/4885CDK2 2/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | CDK9 26/4885CDK1 1/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.